102 related articles for article (PubMed ID: 22850098)
1. [Analysis of prescriptions associated to hormone replacement therapy in Midi-Pyrénées region].
Gass-Jégu F; Damase-Michel C; Hurault-Delarue C; Bourrel R; Montastruc JL
Therapie; 2012; 67(2):121-8. PubMed ID: 22850098
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase.
Espié M; Daures JP; Chevallier T; Mares P; Micheletti MC; De Reilhac P
Gynecol Endocrinol; 2007 Jul; 23(7):391-7. PubMed ID: 17701770
[TBL] [Abstract][Full Text] [Related]
3. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy.
Ettinger B; Pressman A
Am J Manag Care; 1999 Jun; 5(6):779-85. PubMed ID: 10538456
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer in postmenopausal women with and without hormone replacement therapy: preliminary results of the MISSION study.
Espié M; Mares P; de Reilhac P; Chevallier T; Daurès JP
Gynecol Endocrinol; 2006 Aug; 22(8):423-31. PubMed ID: 17012103
[TBL] [Abstract][Full Text] [Related]
5. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen.
Ettinger B; Pressman A; Bradley C
Menopause; 1998; 5(3):152-6. PubMed ID: 9774760
[TBL] [Abstract][Full Text] [Related]
6. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
8. Use of menopausal hormones in the United States, 1992 through June, 2003.
Wysowski DK; Governale LA
Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):171-6. PubMed ID: 15386701
[TBL] [Abstract][Full Text] [Related]
9. Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003.
Hing E; Brett KM
Obstet Gynecol; 2006 Jul; 108(1):33-40. PubMed ID: 16816053
[TBL] [Abstract][Full Text] [Related]
10. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
11. [Prescription of drugs with ASMR V in patients over 65 years in a primary care ambulatory setting. Drug prescription analysis in the Midi-Pyrénées region (France)].
Bismuth S; Chalvignac C; Bagheri H; Oustric S
Rev Prat; 2010 Dec; 60(10 Suppl):3-7. PubMed ID: 22530269
[TBL] [Abstract][Full Text] [Related]
12. Comparative cardiovascular effects of different progestins in menopause.
Rosano GM; Fini M
Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
[TBL] [Abstract][Full Text] [Related]
13. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database.
Faulkner DL; Young C; Hutchins D; McCollam JS
Menopause; 1998; 5(4):226-9. PubMed ID: 9872489
[TBL] [Abstract][Full Text] [Related]
14. Effects of hormone replacement therapy on insulin resistance and platelet function tests.
Saraç F; Saydam G; Sahin F; Oztekin K; Saygili F; Tüzün M; Yilmaz C
Med Princ Pract; 2009; 18(1):43-7. PubMed ID: 19060490
[TBL] [Abstract][Full Text] [Related]
15. Effect of different hormonal replacement therapies on circulating allopregnanolone and dehydroepiandrosterone levels in postmenopausal women.
Bernardi F; Pieri M; Stomati M; Luisi S; Palumbo M; Pluchino N; Ceccarelli C; Genazzani AR
Gynecol Endocrinol; 2003 Feb; 17(1):65-77. PubMed ID: 12724021
[TBL] [Abstract][Full Text] [Related]
16. Haemostatic variables and menopausal status: influence of hormone replacement therapy.
Scarabin PY; Plu-Bureau G; Bara L; Bonithon-Kopp C; Guize L; Samama MM
Thromb Haemost; 1993 Oct; 70(4):584-7. PubMed ID: 8115983
[TBL] [Abstract][Full Text] [Related]
17. Use of hormone replacement therapy in the Hong Kong public health sector after the Women's Health Initiative trial.
Leung KY; Ling M; Tang GW
Maturitas; 2005; 52(3-4):277-85. PubMed ID: 15950409
[TBL] [Abstract][Full Text] [Related]
18. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
[TBL] [Abstract][Full Text] [Related]
19. Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study.
Faber A; Bouvy ML; Loskamp L; van de Berg PB; Egberts TC; de Jong-van den Berg LT
Br J Clin Pharmacol; 2005 Dec; 60(6):641-7. PubMed ID: 16305589
[TBL] [Abstract][Full Text] [Related]
20. Hormone replacement therapy among Danish women aged 45-65 years: prevalence, determinants, and compliance.
Oddens BJ; Boulet MJ
Obstet Gynecol; 1997 Aug; 90(2):269-77. PubMed ID: 9241307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
